Patents by Inventor Howard Fingert

Howard Fingert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
    Patent number: 7795232
    Abstract: The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed to a method of preventing or treating a bcl-2 related disorder, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention is further drawn to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to cancer therapeutics. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may comprise one or more cancer therapeutic agents.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: September 14, 2010
    Assignee: Genta Incorporated
    Inventors: Raymond P. Warrell, Robert E. Klem, Howard Fingert
  • Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
    Publication number: 20100216867
    Abstract: The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed to a method of preventing or treating a bcl-2 related disorder, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention is further drawn to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to cancer therapeutics. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may comprise one or more cancer therapeutic agents.
    Type: Application
    Filed: April 2, 2010
    Publication date: August 26, 2010
    Applicant: Genta Incorporated
    Inventors: Raymond P. Warrell, JR., Howard Fingert, Robert Klem